The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
PIPETTE 4R Tau and Alpha-Synuclein PET Tracer Development, 2021Characterization of PET Tracers for Alpha-synuclein and 4R Tau
Study Rationale:
Parkinson’s disease (PD) is a brain disease characterized by slow movement, rest tremor and stiffness. In most cases the underlying cause is an aggregation of a protein called alpha... -
Improved Biomarkers and Clinical Outcome Measures, 2021Isolating Olfactory Biomarkers of Early Parkinson’s Disease
Study Rationale:
Recently, researchers discovered a specific set of molecules in the oily substance produced by the skin of people with Parkinson’s disease (PD). The findings stemmed from work with a... -
PIPETTE 4R Tau and Alpha-Synuclein PET Tracer Development, 2021Development of a New Class of PET Tracers for Imaging Tau and Alpha-synuclein
Study Rationale:
Parkinson’s disease (PD), Alzheimer’s disease and progressive supranuclear palsy are all characterized by the presence of abnormal aggregations of two proteins in the brain: alpha... -
Fall 2021 RFP: Accelerating Early Proof-of-Concept Testing of Promising PD Therapies, 2021Using Nanobodies and Peptide Mimetics to Stabilize and Activate Mutant GBA
Study Rationale:
Mutations in the gene encoding the enzyme GBA1 are among the most common genetic risk factors for Parkinson’s disease (PD). These mutations compromise the stability and activity... -
Expanding Biological Understanding of PD, 2021Illuminating the Dark Genome of Parkinson’s Disease
Study Rationale:
Over the past two decades, the discovery of dozens of genes involved in Parkinson’s disease (PD) has provided a tremendous opportunity to better understand how the disorder develops... -
PIPETTE 4R Tau and Alpha-Synuclein PET Tracer Development, 2021Development of Selective Markers for Imaging Abnormal Protein Aggregates in Parkinson’s Disease
Study Rationale:
In neurological disorders such as Parkinson’s disease (PD) or frontotemporal dementia, the proteins alpha-synuclein or tau are structurally altered and accumulate in clumps in the...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.